Impact of the COVID-19 Pandemic on Treatment of Patients With STEMI
Primary percutaneous coronary intervention procedures for STEMI significantly decreased during the COVID-19 pandemic.
Primary percutaneous coronary intervention procedures for STEMI significantly decreased during the COVID-19 pandemic.
There was a large national increase in overdose-related cardiac arrests during the initial months of the COVID-19 pandemic.
Direct oral anticoagulant (DOAC) use is not associated with a reduction in the risk for severe COVID-19.
Study authors assess the association between statin therapy and in-hospital mortality in patients with COVID-19 and concomitant diabetes mellitus.
Treatment with beta-blockers vs amiodarone, calcium channel blockers, or digoxin was associated with improved heart control at 1, but not 6 hours in patients with sepsis and atrial fibrillation.
Prolongation of the QTc interval was found to be prevalent after 7 days of hospitalization for COVID-19.
Investigators identified prognostic markers associated with mortality in patients with COVID-19 and concomitant atrial fibrillation or atrial flutter.
Patients who are hospitalized with COVID-19 and have an elevated vs normal troponin levels were found to be at higher risk for death.
Study authors assessed the association between mortality and age, history of cardiac surgery, and other risk factors in patients undergoing surgery for infective endocarditis.